The US Supreme Court is set to hear several pharma-related cases for the term that began Oct. 1. Drug makers are parties in two cases: one involving the on-sale bar to patentability and the other concerning failure-to-warn claims in product liability litigation. Two other cases could also impact the industry: a dispute over the application of the America Invents Act and a case involving class action certification and the deadline for filing an appeal.
The high court has denied several pharma petitions in the past month, while others have recently been filed. It also...





